Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment

(2015) Alberto M. Martelli et al.   Oncotarget

A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia

(2015) Francesca Chiarini et al.   Oncotarget

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades

(2015) James Andrew McCubrey et al.   Oncotarget

Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels

(2015) Daniela Bressanin et al.   Oncotarget

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance

(2015) James Andrew McCubrey et al.   Oncotarget

Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells

(2015) Håkon Reikvam et al.   Oncotarget

Advances in understanding the leukaemia microenvironment

(2014) Yoko Tabe et al.   BRITISH JOURNAL OF HAEMATOLOGY

Antimitotic drugs in cancer chemotherapy: Promises and pitfalls

(2013) Isabel Marzo et al.   BIOCHEMICAL PHARMACOLOGY

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia

(2013) Hagop M. Kantarjian et al.   CANCER

The PTEN-Akt pathway impacts the integrity and composition of mitotic centrosomes

(2013) Mary Leonard et al.   CELL CYCLE

A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis

(2013) James Foran et al.   Clinical Lymphoma Myeloma & Leukemia

Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): A systematic review

(2013) Janet M. Schloss et al.   CLINICAL NUTRITION

Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells

(2013) S. A. Hartsink-Segers et al.   HAEMATOLOGICA

Relapsed childhood acute lymphoblastic leukaemia

(2013) Deepa Bhojwani et al.   LANCET ONCOLOGY

Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia

(2013) A Lonetti et al.   LEUKEMIA

Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling

(2013) F Buontempo et al.   LEUKEMIA

Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase Inhibitor

(2013) P. Farrell et al.   MOLECULAR CANCER THERAPEUTICS

Targeting nuclear kinases in cancer: Development of cell cycle kinase inhibitors

(2013) Todd M. Pitts et al.   PHARMACOLOGY & THERAPEUTICS

PDK1 Signaling Toward PLK1-MYC Activation Confers Oncogenic Transformation, Tumor-Initiating Cell Activation, and Resistance to mTOR-Targeted Therapy

(2013) J. Tan et al.   Cancer Discovery

New Connections between Old Pathways: PDK1 Signaling Promotes Cellular Transformation through PLK1-Dependent MYC Stabilization

(2013) J. T. Cunningham et al.   Cancer Discovery

Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?

(2012) C.-H. Pui et al.   BLOOD

Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia

(2012) Francesca Buontempo et al.   CELL CYCLE

A Small-Molecule Inhibitor Targeting the Mitotic Spindle Checkpoint Impairs the Growth of Uterine Leiomyosarcoma

(2012) W. Shan et al.   CLINICAL CANCER RESEARCH

Mitosis-Targeting Natural Products for Cancer Prevention and Therapy

(2012) Chinthalapally V. Rao et al.   CURRENT DRUG TARGETS

Targeting of polo-like kinases and their cross talk with Aurora kinases – possible therapeutic strategies in human acute myeloid leukemia?

(2012) Galina Tsykunova et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Involvement of Polo-like Kinase 1 (Plk1) in Mitotic Arrest by Inhibition of Mitogen-activated Protein Kinase-Extracellular Signal-regulated Kinase-Ribosomal S6 Kinase 1 (MEK-ERK-RSK1) Cascade

(2012) Ran Li et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The molecular basis of T cell acute lymphoblastic leukemia

(2012) Pieter Van Vlierberghe et al.   JOURNAL OF CLINICAL INVESTIGATION

Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia

(2012) C Simioni et al.   LEUKEMIA

Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib)

(2012) Fei Fei et al.   Molecular Cancer

Regulation of the ERK pathway in the dentate gyrus by in vivo dopamine D1 receptor stimulation requires glutamatergic transmission

(2012) Giuseppe Gangarossa et al.   NEUROPHARMACOLOGY

The potential role of Aurora kinase inhibitors in haematological malignancies

(2011) Sherif S. Farag   BRITISH JOURNAL OF HAEMATOLOGY

Small Molecule Kinase Inhibitor Screen Identifies Polo-Like Kinase 1 as a Target for Neuroblastoma Tumor-Initiating Cells

(2011) Natalie Grinshtein et al.   CANCER RESEARCH

Targeting Aurora Kinases in Cancer Treatment

(2011) Kevin R. Kelly et al.   CURRENT DRUG TARGETS

Polo-Like Kinase 1 Is a Potential Therapeutic Target in Human Melanoma

(2011) Ahmad Jalili et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens

(2011) Y. Hikichi et al.   MOLECULAR CANCER THERAPEUTICS

Polo-like Kinase 1 (Plk1) as a Novel Drug Target in Chronic Myeloid Leukemia: Overriding Imatinib Resistance with the Plk1 Inhibitor BI 2536

(2010) K. V. Gleixner et al.   CANCER RESEARCH

Targeting Polo-like Kinase in Cancer Therapy

(2010) Y. Degenhardt et al.   CLINICAL CANCER RESEARCH

Discovery of GSK1070916, a Potent and Selective Inhibitor of Aurora B/C Kinase

(2010) Nicholas D. Adams et al.   JOURNAL OF MEDICINAL CHEMISTRY

Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress

(2010) Shomit Sengupta et al.   MOLECULAR CELL

Polo-like-kinase 1 (PLK1) as a molecular target to overcome SYK-mediated resistance of B-lineage acute lymphoblastic leukaemia cells to oxidative stress

(2009) Fatih M. Uckun et al.   BRITISH JOURNAL OF HAEMATOLOGY

Therapeutic targeting of microenvironmental interactions in leukemia: Mechanisms and approaches

(2009) Marina Konopleva et al.   DRUG RESISTANCE UPDATES

Aurora Kinases as Anticancer Drug Targets

(2008) O. Gautschi et al.   CLINICAL CANCER RESEARCH

Polo on the Rise—from Mitotic Entry to Cytokinesis with Plk1

(2008) Mark Petronczki et al.   DEVELOPMENTAL CELL

Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery

(2008) Libor Macůrek et al.   NATURE